Nabota, which originated from wild-type Clostridium botulinum, is produced by the guideline of WHO GMP. Nabota was approved by the Korean FDA in 2013, launched in 2014 and contracted for export to 90 countries. Nabota is indicated for the treatment of blepharospasm associated with dystonia, including benign essential blepharospasm, hemifacial spasm or VIIth nerve disorders in patients 12 years or older.

Read more